middle.news
Can Amplia’s Narmafotinib Redefine Pancreatic Cancer Treatment?
8:35am on Wednesday 6th of August, 2025 AEST
•
Healthcare
Read Story
Can Amplia’s Narmafotinib Redefine Pancreatic Cancer Treatment?
8:35am on Wednesday 6th of August, 2025 AEST
Key Points
Median progression-free survival extended to 7.6 months
Objective response rate reaches 31%, surpassing chemotherapy alone
Disease control rate at 73%, significantly higher than benchmark
Tolerability profile comparable to standard chemotherapy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE